Factors affecting progression-free survival in hormone-dependent metastatic breast cancer patients receiving high-dose chemotherapy and hematopoietic progenitor cell transplantation: role of maintenance endocrine therapy

[1]  S. Seeber,et al.  Maintenance treatment with medroxyprogesterone acetate in patients with advanced breast cancer responding to chemotherapy: results of a randomized trial , 1999, Breast Cancer Research and Treatment.

[2]  M. Morgan,et al.  Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  P. Goss,et al.  Aromatase inhibitors in the treatment and prevention of breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  A. Buzdar,et al.  Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  P. Richardson,et al.  Status of high-dose chemotherapy for breast cancer: a review. , 2000, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[6]  S. Martino,et al.  Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. , 2000, The New England journal of medicine.

[7]  J. Armitage,et al.  Factors correlated with progression-free survival after high-dose chemotherapy and hematopoietic stem cell transplantation for metastatic breast cancer. , 1999, JAMA.

[8]  D. Berry,et al.  Prognostic and predictive factors for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high-dose chemotherapy with autologous stem-cell support. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Y. Nieto,et al.  High-dose therapy with autologous hematopoietic cell support as salvage treatment for patients with breast cancer who have relapsed after previous high-dose chemotherapy , 1999, Bone Marrow Transplantation.

[10]  H. Roché,et al.  Intensification thérapeutique et autogreffe de cellules souches hématopoïétiques (CSH) dans le traitement des cancers du sein métastatiques : résultats du programme national Pegase 04 , 1999 .

[11]  B. Asselain,et al.  [Intensive chemotherapy and autograft of hematopoietic stem cells in the treatment of metastatic cancer: results of the national protocol Pegase 04]. , 1999, Hematology and Cell Therapy.

[12]  G. Hortobagyi,et al.  Treatment of breast cancer. , 1998, The New England journal of medicine.

[13]  G. Hortobagyi.  Progress in endocrine therapy for breast carcinoma , 1998, Cancer.

[14]  P. Dombernowsky,et al.  Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  R. Paridaens,et al.  Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Exemestane Study Group. , 1997, European journal of cancer.

[16]  P. Zola,et al.  Prognostic factors in metastatic breast cancer patients obtaining objective response or disease stabilization after first-line chemotherapy with epirubicin. Evidence for a positive effect of maintenance hormonal therapy on overall survival. , 1997, Anticancer research.

[17]  M. Piccart,et al.  Characterisation of complete responders to combination chemotherapy for advanced breast cancer: a retrospective EORTC Breast Group study. , 1996, European journal of cancer.

[18]  G. Hortobagyi,et al.  Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  D. Fairclough,et al.  Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  G. Hortobagyi,et al.  Factors predicting long‐term survival for metastatic breast cancer patients treated with high‐dose chemotherapy and bone marrow support , 1994, Cancer.

[21]  R. Mick,et al.  High-dose consolidation therapy with autologous stem-cell rescue in stage IV breast cancer: follow-up report. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  A. Miller,et al.  Reporting results of cancer treatment , 1981, Cancer.

[23]  G. Hortobagyi,et al.  Prognostic factors in metastatic breast cancer treated with combination chemotherapy. , 1979, Cancer research.

[24]  Audenino Rg.  [Malignant tumors of the breast]. , 1960, El Dia medico.

[25]  M. P. Neal.  MALIGNANT TUMORS OF THE MALE BREAST , 1933 .